{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Cabaletta Bio, Inc.
Is Cabaletta Bio, Inc. technically bullish or bearish?
As of May 15, 2025, Cabaletta Bio, Inc. has a mildly bearish technical stance, influenced by a bearish daily moving average and mixed signals from weekly and monthly indicators.
Who are in the management team of Cabaletta Bio, Inc.?
As of March 2022, the management team of Cabaletta Bio, Inc. includes Dr. Steven Nichtberger as Chairman, President, CEO, and Co-Founder, along with independent directors Dr. Catherine Bollard, Dr. Brian Daniels, Mr. Richard Henriques, and Mr. Mark Simon.
What does Cabaletta Bio, Inc. do?
Cabaletta Bio, Inc. is a clinical stage biotechnology company focused on developing engineered T-cell therapies for B cell-mediated autoimmune diseases, with a market cap of approximately $167.74 million and a recent net profit of -$36 million.
How big is Cabaletta Bio, Inc.?
As of Jun 18, Cabaletta Bio, Inc. has a market capitalization of 167.74 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -126.76 million over the latest four quarters. The company reported shareholder's funds of 152.34 million and total assets of 188.98 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
